FSGS causes loss of protein in the urine, high lipids in blood, and other complications. This study is being done to collect information about the possible effects of a new medication called RE-021 on urine protein loss in patients with FSGS, as well as other positive and negative effects of the treatment. RE-021 has not been approved by the US Food and Drug Administration for the treatment of FSGS. This study involves being randomly chosen to take either RE-021, or a medicine already used to treat FSGS called irbesartan. You will have a 75% chance of receiving RE-021 and a 25% chance of receiving irbesartan. Neither you nor the doctors will know which treatment you are taking. After 8 weeks, all patients in the study will then receive RE-021 for about 40 weeks, even if they were previously assigned to take irbesartan.
You MIGHT be eligible to participate if you:
You CANNOT participate if you:
how to get involved
For more information or to participate, please contact:
Emily Herreshoff, CCRP
Phone: (734) 232-4852